Bayspair
Bayspair Inc. is a Mountain View, California-based genome-editing technology provider (founded 2022) that uses a proprietary nuclease system and Two-step HDR Scarless Editing to offer pre-made iPS cell lines, custom editing services, and technology licensing to academic researchers and for-profit biotech, pharma, and therapeutic customers globally.
- Company typePrivate
- Founded2022
- HeadquartersMountain View, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Bayspair does
Bayspair Inc. is a privately held genome-editing technology provider founded in 2022 and headquartered at 319 Bernardo Avenue, Mountain View, California. The company builds and commercializes a proprietary engineered nuclease system that operates independently from CRISPR/Cas9, enabling targeted sequence destruction or insertion with guide RNA. Its core technical differentiator is a Two-step HDR method supporting 'Scarless Editing' — precise genome rewriting (single-base substitutions, 100+ base insertions, multigenotype edits) without leaving genetic scars — including an Off Guide Editing capability that allows edits thousands of bases away from the nuclease cut site. All editing technologies are described as 100% owned or exclusively licensed by Bayspair, with sub-licensing rights available across research, industrial, therapeutic, diagnostic, and agricultural applications.
Bayspair monetizes through three primary streams: (1) a self-serve catalog and e-commerce storefront selling pre-made genome-edited iPS cell lines (reporter lines at $6,000-$10,000, SNP-edited lines at $7,500-$12,500, base iPS lines at $3,000-$5,000 for non-profits); (2) custom genome-editing services priced from $20,000, including a free catalog-listing request option and a non-disclosure tier at $8,000 plus $1,000 per additional year, with express delivery tiers up to $20,000; and (3) annual technology licensing for for-profit institutions, convertible to perpetual at three times the annual price. Free catalog requests that ultimately produce commercial catalog listings carry a 40% discount. The company serves academic research institutions, individual researchers, and for-profit biotech and pharma customers, with stated market scope spanning the United States, the European Union, and Japan, and with CCPA and GDPR compliance programs in place.
Operationally, Bayspair runs with 1-10 employees, blends a sales-led motion for licensing with a product-led e-commerce motion for catalog cells, and relies primarily on its website as the customer-acquisition channel. It has one disclosed funding round of approximately $3.5M closed in July 2022 with unknown investors, and it does not disclose named customers, revenue, or ownership structure. The business model is best characterized as an early-stage biotech tools and IP-licensing venture commercializing proprietary editing chemistry through catalog products, custom services, and enterprise licensing.
Bayspair firmographics
Firmographics- Name
- Bayspair
- Legal name
- Bayspair Inc.
- Website
- https://bayspair.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bayspair Inc. is a Mountain View, California-based genome-editing technology provider (founded 2022) that uses a proprietary nuclease system and Two-step HDR Scarless Editing to offer pre-made iPS cell lines, custom editing services, and technology licensing to academic researchers and for-profit biotech, pharma, and therapeutic customers globally.
- Ownership category
- akta.pro rank
Bayspair industry classification
Industry- Product category
- Genome Editing Services
- akta.pro primary industry
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
- akta.pro secondary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
Keywords
Where Bayspair is headquartered
LocationHeadquarters
- HQ city
- Mountain View
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bayspair business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Genome Editing Services: Custom genome editing services using Bayspair's proprietary Scarless Editing technology. Services include catalog listing requests (no cost option), non-disclosure catalog listings, and custom genome editing projects. Revenue varies by service type and complexity.
- Genome-Edited Cell Products: Sale of pre-made genome-edited iPS cells including reporter cell lines and cells with disease-associated SNPs. Products sold directly through e-commerce platform with tiered pricing for non-profit vs for-profit institutions.
- Technology Licensing: Licensing of proprietary genome editing technology for research, industrial, therapeutic, diagnostic, and agricultural commercial applications. Includes sub-licensing rights. Genome-edited cells created through services can be commercially used through seamless licensing agreements.
- Subscription Licenses: Annual subscription licensing model for for-profit institutions covering all employees including subsidiaries. Subscriptions can be converted to perpetual licenses by paying three times the price.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Catalog Listing Request (Option A) - Free genome editing request |
| Subscription | Multi-year contract | Non-Disclosure Catalog Listing Request (Option B) - Confidential genome editing |
| Unit Pricing | Pay-as-you-go | Custom Genome Editing Service - Using customer's cells |
| Unit Pricing | Pay-as-you-go | SNP Editing - Single nucleotide substitution |
| Unit Pricing | Pay-as-you-go | Reporter Lines - Fluorescent/luminescent protein insertion |
| Unit Pricing | Pay-as-you-go | iPS Cell Lines - Genome-edited cells |
| Subscription | Annual | For-Profit Institution License |
| Other | Pay-as-you-go | Express Delivery Options |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Bayspair product offering
Product offeringCore offering
Bayspair provides genome editing services and genome-edited iPS cell products using its proprietary nuclease system and Two-step HDR (Scarless Editing) technology, which operates independently from CRISPR/Cas9. The company sells pre-edited reporter and SNP cell lines through an online store, performs custom editing projects using customers' own cell lines on a contingency fee basis, and licenses its editing technology for research, industrial, therapeutic, diagnostic, and agricultural applications.
Product overview
Bayspair is a genome editing technology provider offering a portfolio of products and services centered around its proprietary Scarless Editing Technology and Two-step HDR methodology. The core offerings include an iPS cell bank with genome-edited cells (reporter lines and SNP-modified cells), genome editing services using the company's proprietary nuclease system (which replaces CRISPR/Cas9), and technology licensing for research, industrial, and clinical applications. The company's flagship technologies—Bayspair's Original CRISPR nuclease and Two-step HDR—are available both as services and for licensing. Products are offered at multiple price tiers with catalog listing requests starting at $3,000, custom SNP editing at $12,500, and reporter lines at $10,000 per line for non-profit institutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Genome-Edited iPS Cell Bank
Quantifiable outcome
- 40% off discount automatically applied to customers who requested catalog-listed cells
- +1 more outcomes
Companies that use Bayspair
Customer profileSegments3 records
Ideal customer profiles3 records
Bayspair technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Bayspair partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Bayspair competitors and assessment
Company assessmentDirect peers
- Synthego: Synthego is a genome engineering services and CRISPR reagent provider offering engineered cells, custom sgRNA synthesis, and knockout cell libraries. Directly comparable to Bayspair in delivering CRISPR-based cell line services to research and therapeutic customers, though Synthego uses CRISPR/Cas9 rather than a proprietary nuclease.
- EditCo Bio (Revvity): EditCo provides custom genome editing services using CRISPR/Cas9 and base editing, producing knock-in/knockout cell lines for research and therapeutic customers. Directly comparable service offering to Bayspair with similar custom cell line delivery model but at larger scale and faster turnaround.
- Cellecta: Cellecta offers custom cell line development, CRISPR libraries, and genetic screening services for research and drug discovery customers. Comparable niche player offering custom genome editing services with similar business model, though focused on screening libraries rather than iPS cell editing.
- Applied StemCell: Applied StemCell provides custom iPSC genome editing services and off-the-shelf edited iPSC lines for research customers. Directly comparable niche peer offering similar iPSC-focused custom editing and catalog products to Bayspair.
Broad incumbents
- Twist Bioscience: Twist Bioscience is a larger DNA synthesis and synthetic biology platform that also offers gene fragments, oligo pools, and CRISPR libraries used in genome editing workflows. Broader incumbent with overlapping customer base in synthetic biology and gene editing, though Twist is primarily a tools/synthesis provider rather than a custom editing service.
- GenScript: GenScript is a global biotech providing gene synthesis, cell line engineering, and custom genome editing services for research and therapeutic customers. Comparable to Bayspair in offering custom cell line modification services but at vastly larger scale across many more service categories.
- Horizon Discovery (Revvity): Horizon Discovery (now part of Revvity) provides cell line engineering, custom gene editing, and knockout/knock-in cell line products for research and drug discovery. Directly comparable in delivering engineered cell lines but operating as part of a much larger life science tools portfolio.
- Inscripta (Revvity): Inscripta (now part of Revvity) developed an automated benchtop genome editing platform (Onyx) and offers CRISPR-based nuclease reagents. Adjacent to Bayspair as a genome editing platform/tools provider, though Inscripta focused on instrumentation rather than custom services.
Others
- Mirus Bio (Roche): Mirus Bio (acquired by Roche) specializes in transfection and transduction reagents used in cell engineering workflows, including genome editing applications. Adjacent rather than directly competing; provides enabling reagents to the genome editing services market that Bayspair serves.
Emerging players
- VectorBuilder: VectorBuilder is a fast-growing gene delivery and vector design services company offering custom AAV, lentiviral, and CRISPR vector construction. Partially overlapping with Bayspair on gene editing workflows but focused on vector/cloning services rather than cell line editing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Bayspair social profiles
Digital presenceBayspair compliance and trust
Trust signalCompliance2 records
Bayspair financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bayspair leadership team
Management profileNumber of profiles
Bayspair funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bayspair M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bayspair
What does Bayspair do?
Bayspair provides genome editing services and genome-edited iPS cell products using its proprietary nuclease system and Two-step HDR (Scarless Editing) technology, which operates independently from CRISPR/Cas9. The company sells pre-edited reporter and SNP cell lines through an online store, performs custom editing projects using customers' own cell lines on a contingency fee basis, and licenses its editing technology for research, industrial, therapeutic, diagnostic, and agricultural applications.
Is Bayspair a public or private company?
Bayspair is a private company. It is classified as unknown and is currently operating.
When was Bayspair founded?
Bayspair was founded in 2022. It employs 1 to 10 people.
Where is Bayspair based?
Bayspair is headquartered in Mountain View, United States, in the North America region.
How does Bayspair make money?
Four revenue lines are on record. Genome Editing Services are the primary driver. The others are genome-Edited Cell Products, technology Licensing and subscription Licenses.
Who are Bayspair's main competitors?
Direct peers on record are Synthego, EditCo Bio (Revvity), Cellecta and Applied StemCell. Broad incumbents are Twist Bioscience, GenScript, Horizon Discovery (Revvity) and Inscripta (Revvity). Mirus Bio (Roche) is listed as an others. VectorBuilder is listed as an emerging player.
Does Bayspair have an API?
No public API is recorded for Bayspair.
What industry is Bayspair in?
Bayspair's product category is Genome Editing Services. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers.